Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Open Tirzepatide (Tirze) in the 3D analyzerAnalytical specification
| Empirical formula | C225H348N48O68 |
|---|---|
| Molecular weight | 4813.5 g/mol |
| Isoelectric point (pI) | 6.12 |
| Assay purity (HPLC) | 99.65% |
| Retention time | 5.90 min |
| Peak area / height | 15120 / 1250 |
| Reference batch | TI-2026-Y89 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-K-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S |
Research characteristics
Insulin Secretion
Glucose-dependent enhancement
Appetite Suppressing
Slows gastric emptying kinetics
Metabolic Profile
Enhances insulin sensitivity parameters
Adipose Targets
Facilitates selective lipid combustion dynamics
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.
Orforglipron
Non-peptide oral small-molecule GLP-1 receptor agonist engineered for high bio-availability trials.